MIAMI BEACH, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ: AIRS) (“AirSculpt” or the “Company”), an industry leader and provider of premium body contouring procedures, today announced that it will participate in investor meetings and host a presentation at the ICR Conference 2025 being held at The Grande Lakes Orlando in Orlando, Florida on January 13, 2025 through January 14, 2025.
Chief Executive Officer, Yogi Jashnani, and Chief Financial Officer, Dennis Dean, will host a presentation on Tuesday, January 14, 2025, at 10:00 a.m. Eastern Standard Time. The presentation will be webcast live at https://investors.airsculpt.com. An archive of the webcast presentation will be available for 90 days.
About AirSculpt
AirSculpt offers a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at its 31 centers in North America and one location in the United Kingdom. The Company’s minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
To learn more about AirSculpt Technologies, please visit the Company's website at https://investors.elitebodysculpture.com. AirSculpt Technologies uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt Technologies is routinely posted on the Company's website and is readily accessible.
Investor Contact
Allison Malkin
ICR, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.20 |
Daily Change: | 0.04 0.96 |
Daily Volume: | 162,434 |
Market Cap: | US$242.810M |
May 02, 2025 December 17, 2024 November 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load